ProCE Banner Activity

A Comprehensive Look at Tardive Dyskinesia Management

Podcast Episodes

In this podcast episode, Robert O. Cotes, MD, and Jonathan M. Meyer, MD, discuss tardive dyskinesia management from identification to follow-up, with a focus on VMAT2 inhibitors as a pharmacologic management strategy.

Released: October 28, 2022

Expiration: October 27, 2023

Share

Faculty

Robert O. Cotes

Robert O. Cotes, MD, DFAPA

Professor and Distinguished Physician
Director, Clinical & Research Program for Psychosis at Grady Health System
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

Jonathan M. Meyer

Jonathan M. Meyer, MD, DLFAPA

Voluntary Clinical Professor of Psychiatry 
University of California, San Diego
Senior Academic Advisor
California Department of State Hospitals
San Diego, California

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from

Teva

Faculty Disclosure

Primary Author

Robert O. Cotes, MD, DFAPA

Professor and Distinguished Physician
Director, Clinical & Research Program for Psychosis at Grady Health System
Department of Psychiatry and Behavioral Sciences
Emory University School of Medicine
Atlanta, Georgia

Robert O. Cotes, MD: researcher: Alkermes, Lundbeck, Otsuka, Roche; independent contractor: Saladax.

Jonathan M. Meyer, MD, DLFAPA

Voluntary Clinical Professor of Psychiatry 
University of California, San Diego
Senior Academic Advisor
California Department of State Hospitals
San Diego, California

Jonathan M. Meyer, MD: consultant/advisor/speaker: Alkermes, Intra-Cellular Therapies, Karuna, Neurocrine, Noven, Otsuka America, Sunovion, Teva.